Subject is between 18 years old and 75 years old, inclusive
Must be at least 5 years old and enrolling on SJMB12
At least 5 years old at time of consent to remediation intervention
>= 11 and < 25 years old at enrollment
Adult (? 18 years old)
Treatment-naive participants with AML who are >/=75 years old
Patients ? 18 years old
Man or woman >= 18 years old.
Patients must be at least 18 years old.
DONOR: < 6 months old and > 75 years old
Subjects 1 and 2 (in cohort 1) will be >= 12 years’ old
Patients 18 to 70 years old
The patient is ?18 years old.
The patient is at least 18 years old.
Patients 0-49 years old will be enrolled in Arm A or C (high-intensity)
Patient must be at least 18 years old at the time of consent.
Patients must be at least 18 years old.
Is aged ?20 years old in Japan or ?18 years old in other countries
Initially only patients who are >= 16 years old will receive HA-1 TCR T cell infusions on the protocol; younger patients may be screened, enrolled in the protocol and monitored for relapse but will not be eligible for infusion until at least one patient >= 16 years old has been treated and discussed with the Food and Drug Administration (FDA)
At least 18 years old at the time of informed consent
Age greater than or equal to 16 years old; if patients 16-17 years old are enrolled in the trial, they will only be enrolled after 3 patients >= 18 years old have been treated, and the treatment has been shown to be safe
Patients ?18 years and ?80 years old (The 3 first patients at Dose Level 1 will be < 65 years old. Enrollment of patients ? 65 years old must be approved by the DSMB after the completion of cohort 1).
Patient is ? 18 years old at the time of informed consent.
Patients enrolled onto the dose-finding phase of the study must have an identified donor and transplant strategy prior to initiation of the lymphodepletion regimen. Patients enrolled in the Expansion Phase of the Study: Relapsed/Refractory Cohort • Patients ?18 years old with relapsed or primary refractory acute myeloid leukemia. Patients Enrolled in the Dose-Escalation Phase of the Study •Patients ?18 years and ?75 years old (The 3 first patients at Dose Level 1 will be <65 years old. Enrollment of patients ? 65 years old must be approved by the DSMB after the completion of cohort 1) Newly Diagnosed Cohort • Patients with newly diagnosed, untreated Acute Myeloid Leukemia (as defined by World Health Organization (WHO) criteria,) who meet criteria for the European Leukemia Net (ELN) Adverse genetics prognostic group. Eligibility criteria for UCART123 administration
Creatinine =< 1.5 mg/dL for patients 12 years old and older and =< 1 for patients younger than 12 years old.
Female ? 18 years old.
IMMUNE RECONSTITUTION STUDY ONLY: Between 8 and 60 years old
DONOR: Must be >= 14 years old
> 18 years old
Patients must be ? 18 years old.
At least 18 years old;
Man or woman >= 18 years old.
DONOR: Less than 18 years old
Male or female patients from 6 months to ? 21 years old at the time of study enrollment
Patients ?18 year old
Patients must be > 18 years old.
Donor: Donor < 6 months old, > 75 years old
The patient is ? 18 years old.
The patient is ? 18 years old.
Participants who are 16 to 17 years old would be enrolled after consultation with the Medical Monitor
Are a male or female patient ?18 years old.
DONOR: Children < 12 years old
Adult Women (? 18 years old).
Be 18 years old at the time the informed consent is signed
?18 years old.
Patient must be ? 18 years old.
Patients must be at least 18 years old.
Men and women ?18 years old.
Are a male or female participants ?18 years old.
Patients ? 16 years old
Patient must be at least 18 years old.
Male or female patients ?18 years old.
Patients 18 years old or greater
Patients > or = 18 years old
? 18 years old at the time of informed consent.
Patients must be >/= 18 years old.
?18 years old
?18 years old
Male or female ?18 years old
Donor >= 18 years old
Male or female patient is ? 18 years old,
Male and female TAM patients ? 2 years old at the time of first dose administration. Patients < 12 years old can only be included in the study after first IA has shown that it is safe and well tolerated in patients ? 12 years old (Section 3.5).
Male or female patients ? 18 years old
Is >18 years old;
Male or female ?18 years old.
Patient is an adult, female ? 18 years old at the time of informed consent
? 18 years old
Men or women > 18 years old
?18 years old, diagnosed with persistent or chronic ITP
Man or woman >= 18 years old.
Subjects >=18 years old.
? 18 years old Part 2, dose expansion:
Is the subject between 18 years old and 80 years old inclusive?
The subject is at least 18 years old.
Patient is an adult ? 18 years old at the time of informed consent.
18-39 years old
Men or women > 18 years old
The patient is ?18 years old.
?18 years old
In patients > 60 years old, documented LVEF of less than or equal to 45%
Patients must be greater than or equal to 18 years old.
Men or women ?18 years old
Male or female patients ?18 years old.
Men or women ? 18 years old
For patients < 60 years old: at least two induction chemotherapy treatments.
For patients >= 60 years old: at least one induction chemotherapy treatment or alternative treatment.
Females at least 18 years old;
Male or female patients >= 18 years old
Patients treated at collaborating sites and current St. Jude patients who are on therapy or within 3 years of completion of therapy must be =< 24 years old; all other St. Jude patients must be =< 21 years old
Subject is female and is at least 18 years old
DCG: Is an adult family member (at least 18 years old) of a patient with an advanced-stage cancer
< 19 years old
< 19 years old
CAREGIVERS ONLY: Must be an adult (>=18 years old)
Are at least 18 years old
Are 8-17 years old
Patients who are in close social contact with children under 5 years old
Adult (?18 years old)
18-35 years old
Male 18 to 60 years old
Female 18 to 50 years old
18-40 years old,
The patient is ?21 years old,
>18 years old.
FLT PET: will only be performed in patients >= 10 years old
Research biopsies in consenting patients with MPNST: will only be performed in patients >= 18 years old
Patient is < 18 years old at the time of the drug administration
?18 years old
M/F at least 18 years old
History of treatment for cancer or related illness diagnosed at =< 25 years old
The patient is at least 18 years old.
Women ? 18 years old
